The Pharmacy of the Specialized Component of Pharmaceutical Policy of the 9th Regional Health Department of the State of Paraná and the Treatment of Ankylosing Spondylitis
DOI:
https://doi.org/10.1590/s2175-97902022e19387Keywords:
Ankylosing Spondylitis, BASDAI, ASQoL, Public healthAbstract
The objective of this study was to trace the profile of patients with Ankylosing Spondylitis treated at the Pharmacy of the 9th Regional Health Department of Paraná and evaluate the relationship between pharmacological treatment, quality of life and disease activity index of these patients. Data collection was performed through interviews, application of BASDAI index and the ASQoL questionnaire. Male patients presented better rates (ASQoL 7.78 ± 6.04, BASDAI 4.26 ± 2.40) than female patients (ASQoL 12.08 ± 4.74, BASDAI 6.25 ± 2.43; p <0.05). Retired patients had higher disease activity and lower quality of life (BASDAI 6.59 ± 1.53, ASQoL 14 ± 2.89) than those who still worked (BASDAI 4.59 ± 2.87, ASQoL 7.68 ± 5.74); p <0.05), and the quality of life of patients with comorbidity (ASQoL 11.60 ± 5.47) was lower when compared to those without comorbidity (ASQoL 6.83 ± 4.90, p <0.05). Patients who used immunobiological drugs had better results (ASQoL 9.07 ± 5.86, BASDAI 4.73 ± 2.55) than those who used other drugs (ASQoL 13.08 ± 3.7, BASDAI 6.88 ± 2.15, p <0.05), and patients who used adalimumab showed better rates (ASQoL 7.42 ± 4.81, BASDAI 4.26 ± 2.47; p <0.05) when compared to other pharmacological treatments. Male patients showed a better response when compared to the female counterparts. Patients using adalimumab had a better quality of life and disease activity index than patients using other pharmacological treatments.
Downloads
References
Azevedo VF, Rossetto CN, Lorencetti PG, Tramontin MY, Fornazari B, Araújo DV. Indirect and direct costs of treating patients with ankylosing spondylitis in the Brazilian public health system. Rev Bras Reumatol. 2016;56(2):131-137.
Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369(9570):1379-1390.
Costa IP, Bortoluzzo AB, Gonçalves CR, Silva JAB, Ximenes AC, Bértolo MB et al. Avaliação do desempenho do BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) numa coorte brasileira de 1.492 pacientes com espondiloartrites: dados do Registro Brasileiro de Espondiloartrites (RBE). Rev Bras Reumatol . 2015;55(1):48-54.
Costa RMD, Monteagudo MDG. Espondilite Anquilosante: o exercício físico como reabilitação e promotor da qualidade de vida. Motri. 2008;4(2):11-20.
Dabés CG, Almeida AM, Acurcio FA. Não adesão à terapia biológica em pacientes com doenças reumáticas no Sistema Único de Saúde em Minas Gerais, Brasil. (Non-adherence to biological therapy in patients with rheumatic diseases in the Brazilian Unified National Health System in Minas Gerais State, Brazil). Cad Saúde Pública. 2015;31:2599-2609.
Davis-Jr JC, Revicki D, van der Heijde DM, Rentz AM, Wong RL, Kupper H et al. Health-Related Quality of Life Outcomes in Patients With Active Ankylosing Spondylitis Treated With Adalimumab: Results From a Randomized Controlled Study. Arthritis Rheum. 2007;57(6):1050-1057.
Doward LC, Spoorenberg A, Cook SA, Whalley D, Helliwell PS, Kay LJ et al. Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis. 2003;62(1):20-26.
Frauendorf R, Pinheiro MM, Ciconelli RM. Variables related to work productivity loss in patients with ankylosing spondylitis. Rev Bras Reumatol . 2013;53(3):303-309.
Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21(12):2286-2291.
Hwang J, Kim HM, Jeong H, Lee J, Ahn JK, Koh EM et al. Higher body mass index and anti-drug antibodies predict the discontinuation of anti-TNF agents in Korean patients with axial spondyloarthritis. Rev Bras Reumatol . 2017;57(4):311-319.
Januário F, Almeida J, Serra S, Amaral C, Machado P, Rodrigues LA. Caracterização de doentes com espondilite anquilosante em hidrocinesiterapia - uma avaliação multidimensional. Acta Med Por. 2012;25(5):301-307.
Mease PJ. Fibromyalgia, a Missed Comorbidity in Spondyloarthritis: Prevalence and Impacton Assessment and Treatment. Curr Opin Rheumatol. 2017;29(4):304-310.
Meirelles ES, Kitadai F. Aspectos clínicos e epidemiológicos da espondilite anquilosante. Rev Bras Reumatol . 1999;39(1):30-34.
Ministério da Saúde (Brasil). Componente Especializado da Assistência Farmacêutica: inovação para a garantia do acesso a medicamentos no SUS. 2014b.
Ministério da Saúde (Brasil). Portaria Conjunta SAS - SCTIE/MS nº 7, de 17 de julho de 2017. Aprova o Protocolo Clínico e Diretrizes Terapêuticas da Espondilite Ancilosante. Diário Oficial da União 19 jul 2017; Seção 1.
Ministério da Saúde (Brasil). Portaria Conjunta SAS/MS nº 640, de 24 de julho de 2014a. Aprova o Protocolo Clínico e Diretrizes Terapêuticas da Espondilite Ancilosante. Diário Oficial da União 24 de jul 2014; Seção 1.
Ribeiro SLE, Albuquerque EN, Bortoluzzo AB, Gonçalves CR, Braga da Silva JA, Ximenes AC, et al. Quality of life in spondyloarthritis: analysis of a large Brazilian cohort. Rev Bras Reumatol . 2016;56(1):22-27.
Sampaio-Barros PD, Azevedo VF, Bonfiglioli R, Campos WR, Carneiro SCS, Carvalho MAP, et al. Consenso Brasileiro de Espondiloartropatias: Espondilite Anquilosante e Artrite Psoriásica Diagnóstico e Tratamento - Primeira Revisão. Rev Bras Reumatol . 2007;47(4):233-242.
Torres TM, Ferraz MB, Ciconelli RM. Instrumentos de Avaliação em Espondilite Anquilosante. Rev Bras Reumatol . 2006;46:52-59.
Vieira FS. Assistência farmacêutica no sistema público de saúde no Brasil. Rev Panam Salud Publica. 2010;27(2):149-56.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on line journal has open and free access.
